Slow Clearance of Human Parvovirus B19 Viremia following Acute Infection

Lindblom, Anna; Isa, Adiba; Norbeck, Oscar; Wolf, Susanne; Johansson, Bo; Broliden, Kristina; Tolfvenstam, Thomas

doi:10.1086/444503

Cited by 102 publications

(84 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…57 It has been reported that B19V DNA may be detectable by PCR for extended periods of up to years in bone marrow and even serum. 58 Donor-derived nosocomial infection has also been described (blood products; stem cells). 1,59 The infection has been seen in association with other post-transplant complications, such as allograft dysfunction, hepatitis, myocarditis and glomerulonephritis, and post-transplant mortality directly attributable to B19V has been estimated at 3%.…”

Section: Discussionmentioning

confidence: 99%

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Rahiala

Koskenvuo

Norja

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

Among the immunocompetent, infections with parvovirus B19 (B19V) and human bocavirus (HBoV) 1 range clinically from asymptomatic to severe, while following allogeneic hematopoietic SCT (HSCT) B19V can cause a persistent severe illness. The epidemiology and clinical impact of HBoV1 and the other emerging parvovirus 4 (PARV4) among immunocompromised patients have not been established. To determine the occurrence and clinical spectrum of B19V, PARV4 and HBoV1 infections, we performed a longitudinal molecular surveillance among 53 allogeneic HSCT recipients for pre-and post-HSCT DNAemias of these parvoviruses. Quantitative real-time PCR showed B19V DNA in sera of 16 (30%) patients, at mean levels of 4.6 Â 10 3 , 9.9 Â 10 7 , 1.1 Â 10 10 and 1.6 Â 10 2 B19V DNA copies/mL pre-HSCT (9/53), and at 1 (6/53), 2 (4/53) and 3 months (1/25) post HSCT, respectively. However, no clinical manifestation correlated with the presence of B19V viremia. All B19V sequences were of genotype 1. None of the sera investigated contained PARV4 or HBoV1 DNAs. Our data demonstrate B19V viremia to be frequent among pediatric allogeneic HSCT recipients, yet without apparent clinical correlates. PARV4 or HBoV1 viremias were not seen in these immunocompromised patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Rahiala

Koskenvuo

Norja

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…First, HBoV is not related to a known human respiratory pathogen. Second, HBoV may be shed persistently, since other human parvoviruses (B19V, PARV4, and the AAVs) have the capacity for asymptomatic persistence (41,44,50). Third, HBoV is commonly detected in association with other respiratory viruses which have an established pathogenic potential.…”

Section: Hbov and Respiratory Tract Diseasementioning

confidence: 99%

Human Bocavirus: Passenger or Pathogen in Acute Respiratory Tract Infections?

et al. 2008

View full text Add to dashboard Cite

SUMMARY Human bocavirus (HBoV) is a newly identified virus tentatively assigned to the family Parvoviridae, subfamily Parvovirinae, genus Bocavirus. HBoV was first described in 2005 and has since been detected in respiratory tract secretions worldwide. Herein we review the literature on HBoV and discuss the biology and potential clinical impact of this virus. Most studies have been PCR based and performed on patients with acute respiratory symptoms, from whom HBoV was detected in 2 to 19% of the samples. HBoV-positive samples have been derived mainly from infants and young children. HBoV DNA has also been detected in the blood of patients with respiratory tract infection and in fecal samples of patients with diarrhea with or without concomitant respiratory symptoms. A characteristic feature of HBoV studies is the high frequency of coinciding detections, or codetections, with other viruses. Available data nevertheless indicate a statistical association between HBoV and acute respiratory tract disease. We present a model incorporating these somewhat contradictory findings and suggest that primary HBoV infection causes respiratory tract symptoms which can be followed by prolonged low-level virus shedding in the respiratory tract. Detection of the virus in this phase will be facilitated by other infections, either simply via increased sample cell count or via reactivation of HBoV, leading to an increased detection frequency of HBoV during other virus infections. We conclude that the majority of available HBoV studies are limited by the sole use of PCR diagnostics on respiratory tract secretions, addressing virus prevalence but not disease association. The ability to detect primary infection through the development of improved diagnostic methods will be of great importance for future studies seeking to assign a role for HBoV in causing respiratory illnesses.

show abstract

“…However, emerging evidence challenges this notion. With the use of sensitive quantitative techniques such as dot blot and nested PCR assays, B19 DNA has been detected in bone marrow and in peripheral blood for months and even years in seemingly immunocompetent individuals, despite the presence of neutralizing antibody (29,30). The clinical significance of this delayed clearance and low-level viremia is unknown.…”

Section: Pathogenesis and Immune Responsementioning

confidence: 99%